167 related articles for article (PubMed ID: 18182997)
1. Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells.
Lagadec P; Griessinger E; Nawrot MP; Fenouille N; Colosetti P; Imbert V; Mari M; Hofman P; Czerucka D; Rousseau D; Berard E; Dreano M; Peyron JF
Br J Cancer; 2008 Jan; 98(2):335-44. PubMed ID: 18182997
[TBL] [Abstract][Full Text] [Related]
2. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
Cusack JC; Liu R; Houston M; Abendroth K; Elliott PJ; Adams J; Baldwin AS
Cancer Res; 2001 May; 61(9):3535-40. PubMed ID: 11325813
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents.
Sors A; Jean-Louis F; Bégué E; Parmentier L; Dubertret L; Dreano M; Courtois G; Bachelez H; Michel L
Clin Cancer Res; 2008 Feb; 14(3):901-11. PubMed ID: 18245554
[TBL] [Abstract][Full Text] [Related]
4. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
Tang W; Su G; Li J; Liao J; Chen S; Huang C; Liu F; Chen Q; Ye Y
Int J Oncol; 2014 Sep; 45(3):995-1010. PubMed ID: 24968890
[TBL] [Abstract][Full Text] [Related]
5. Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth.
Jourdan M; Moreaux J; Vos JD; Hose D; Mahtouk K; Abouladze M; Robert N; Baudard M; Rème T; Romanelli A; Goldschmidt H; Rossi JF; Dreano M; Klein B
Br J Haematol; 2007 Jul; 138(2):160-8. PubMed ID: 17542984
[TBL] [Abstract][Full Text] [Related]
6. Calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts.
Fenouille N; Grosso S; Yunchao S; Mary D; Pontier-Bres R; Imbert V; Czerucka D; Caroli-Bosc FX; Peyron JF; Lagadec P
J Pathol; 2012 May; 227(1):118-29. PubMed ID: 22069124
[TBL] [Abstract][Full Text] [Related]
7. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
Allegrini G; Goulette FA; Darnowski JW; Calabresi P
Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
[TBL] [Abstract][Full Text] [Related]
8. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
9. Bromoethylindole (BEI-9) redirects NF-κB signaling induced by camptothecin and TNFα to promote cell death in colon cancer cells.
Chowdhury R; Gales D; Valenzuela P; Miller S; Yehualaeshet T; Manne U; Francia G; Samuel T
Apoptosis; 2017 Dec; 22(12):1553-1563. PubMed ID: 29116428
[TBL] [Abstract][Full Text] [Related]
10. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ
Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960
[TBL] [Abstract][Full Text] [Related]
11. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation.
Cusack JC; Liu R; Baldwin AS
Cancer Res; 2000 May; 60(9):2323-30. PubMed ID: 10811101
[TBL] [Abstract][Full Text] [Related]
12. The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo.
Nair JS; de Stanchina E; Schwartz GK
Clin Cancer Res; 2009 Mar; 15(6):2022-30. PubMed ID: 19276280
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis.
Beraza N; Malato Y; Vander Borght S; Liedtke C; Wasmuth HE; Dreano M; de Vos R; Roskams T; Trautwein C
Gut; 2008 May; 57(5):655-63. PubMed ID: 18408102
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines.
Tagoug I; Sauty De Chalon A; Dumontet C
PLoS One; 2011; 6(7):e22641. PubMed ID: 21799925
[TBL] [Abstract][Full Text] [Related]
16. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
[TBL] [Abstract][Full Text] [Related]
17. The antitumor effect of a novel differentiation inducer, 2, 2-Bis (4-(4-amino-3-hydroxyphenoxy) phenyl) adamantane (DPA), in combinatory therapy on human colon cancer.
Wang JJ; Lee JY; Chen YC; Chern YT; Chi CW
Int J Oncol; 2006 Apr; 28(4):1003-12. PubMed ID: 16525652
[TBL] [Abstract][Full Text] [Related]
18. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.
Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S
Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.
Motwani M; Jung C; Sirotnak FM; She Y; Shah MA; Gonen M; Schwartz GK
Clin Cancer Res; 2001 Dec; 7(12):4209-19. PubMed ID: 11751522
[TBL] [Abstract][Full Text] [Related]
20. Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells.
Frelin C; Imbert V; Griessinger E; Peyron AC; Rochet N; Philip P; Dageville C; Sirvent A; Hummelsberger M; Bérard E; Dreano M; Sirvent N; Peyron JF
Blood; 2005 Jan; 105(2):804-11. PubMed ID: 15454494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
